Acurx Q2 Loss Narrows to $2.25M; FDA Path for Ibezapolstat Advances
ACXP sits 23% above its 52-week low of $1.326 on elevated volume (2.8× avg).
Summary
Acurx reported a Q2 net loss of $2.25 million, consistent with the 10-Q filed yesterday, and reiterated its going concern warning with $10.7 million in cash. The company highlighted FDA meeting minutes from August 3 outlining a potential streamlined path to approval for ibezapolstat in C. difficile infection, plus conditional acceptance of the proprietary name and new patents in Japan and Mexico. The April registered direct offering raised funds at $3.03 per share, above the current $1.63 price, but the company still needs additional capital. The conference call today will provide management's outlook on the pivotal Phase 3 trial design and financing plans.
At the time of this announcement, ACXP was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $1.33 to $8.34. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.